Figure 6.

Discovery and validation of α1-antitrypsin as a biomarker for predicting survival of pancreatic cancer patients following chemotherapy (partially changed from [11]). (a) 2DICAL images of the peak (m/z, 508; RT, 48.9 min) with coordinates RT versus patients (upper) and intensity versus patients (lower). Red indicates samples from pancreatic cancer patients with short-term survival, and blue indicates samples from pancreatic cancer patients with long-term survival. (b) Western blot of α1-antitrypsin and the loading control Complement C3b-α. (c) Large-scale RPPA validation of the plasma level of α1-antitrypsin using hundreds of clinical samples. Survival curve was significantly better in the group of low α1-antitrypsin level than that of high α1-antitrypsin level.